PTC Therapeutics, Inc.NASDAQ: PTCT

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

· Issued by PTC Therapeutics, Inc. via PR Newswire

Summary by 6ix AI

PTC Therapeutics, a biopharmaceutical company developing medicines for rare disorders, will host a webcast conference call to report its third quarter 2026 financial results and give a business update on Thursday, October 29, 2026, at 4:30 p.m. ET.

Key details

  • The live webcast will be on the Events & Presentations page in the Investors section of the PTC website, and a replay will be available there for 30 days after the event.
  • Phone participants must register in advance to receive dial-in details.

6ix AI wrote this summary from the release below and checked it against the release.

WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m. ET.

To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook and Instagram.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

SOURCE PTC Therapeutics, Inc.

View original source (PR Newswire)PTC Therapeutics, Inc. on 6ix

Earlier from PTC Therapeutics

All PTC Therapeutics news releases